Zylacta Overview

  • Founded
  • 2004
Founded
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 1

Zylacta General Information

Description

Operator of a biotechnology company intended to develop small molecule therapeutics. The company's therapeutics are based on bacterial cell wall peptidoglycan for immunotherapy and also offer methods to develop these hits into drugs via a gene-based technology, enabling clients to get expertise in genomics of bacterial peptidoglycan synthesis, maturation and shedding.

Contact Information

Website
www.zylacta.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 7965 Cessna Avenue
  • Gaithersburg, MD 20879
  • United States
+1 (410) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zylacta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-May-2021 00000 Completed Generating Revenue
3. Grant 21-Feb-2008 00000 00000 Completed Generating Revenue
2. Early Stage VC 03-Nov-2006 $225K $225K Completed Startup
1. Grant 26-Sep-2006 $75K Completed Startup
To view Zylacta’s complete valuation and funding history, request access »

Zylacta Patents

Zylacta Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20040258779-A1 A cytoprotective soy isoflavone and peptidoglycan of lactobacillus plantarum, n-acetyl-glucosamine-n-acetyl-muramyl-l-alanine-d-isoglutamine-meso-diaminopimelyl-d-alanine; antiapoptotic agents; humans and domesticated animals Abandoned 06-Jun-2003 0000000000 0
US-20050059579-A1 Inhibition of tumor necrosis factor-alpha prooxidant action via administration of biodegradable n-acetyl-glucosamine-n-acetyl-muramyl-peptides released after endopeptidase and lysozyme digestion of genus lactobacillus and bifidum; for conditions with elevated gamma glutamyl transpeptidase activity Abandoned 06-May-2003 0000000000 0
CA-2521718-A1 Biodegradable glucosaminemuramyl peptides for apoptosis modulation Abandoned 09-Apr-2003 000000000
US-20040203090-A1 Formed via endopeptidase hydrolysis of peptide bond of the peptidoglycans; gram positive bacteria; cytoprotective agents capable of inhibiting of tumor necrosis factor alpha cytotoxicity; treating cardiovascular disorders Granted 09-Apr-2003 000000000 0
US-7112564-B2 Formed via endopeptidase hydrolysis of peptide bond of the peptidoglycans; gram positive bacteria; cytoprotective agents capable of inhibiting of tumor necrosis factor alpha cytotoxicity; treating cardiovascular disorders Expired - Fee Related 09-Apr-2003 C07K9/005 0
To view Zylacta’s complete patent history, request access »

Zylacta Executive Team (6)

Name Title Board Seat Contact Info
Robert Shalwitz MD Co-Founder & President
Stephen Cohen Chief Financial Officer
Vladimir Slesarev Jr. Chief Information Officer
Nikolai Polouchine Chief Scientific Officer
You’re viewing 4 of 6 executive team members. Get the full list »

Zylacta Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Maryland Industrial Partnerships University 000 0000 000000 0
To view Zylacta’s complete investors history, request access »